A comprehensive grasp of the mechanisms underlying the IL-23/IL-23R pathway and the capacity to modulate it represent indispensable prerequisites for the formulation of novel therapeutics for the treatment of immune-mediated disorders and cancer. The gene discussed is IL37; the disease is cancer.